Back

Johnson & Johnson presents new IMAAVY data in generalized myasthenia gravis

Verifying
  • Johnson & Johnson presented new IMAAVY data for generalized myasthenia gravis.
  • IMAAVY is identified as nipocalimab-aahu in the material.
  • The data reinforce sustained disease control and improved daily function, according to Johnson & Johnson.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.